Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
Biosimilars Deals 2023
Biosimilars Deals 2024
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Trade Marks

Pearce IP BioBlast™: w/e 24 January 2020

by | Jan 27, 2020

Significant biosimilar activities this week include

Jan 20 | Genentech and Roche commenced recruitment for Ph III clinical trials of their ranibizumab Port Delivery System (PDS) in patients with diabetic macular edema. The PDS uses a refillable eye implant to release a ranibizumab formulation over several months.

23 Jan 20 | Janssen announced the UK’s NICE did not recommend Stelara® (ustekinumab) for moderately to severely active ulcerative colitis, due to uncertainties over cost-effectiveness.

23 Jan 20 | Pfizer announced the launch of its biosimilar rituximab product in the US at a 24% discount to Rituxan®. Pfizer also announced that it will launch its trastuzumab product in the US on 15 February at a 22% discount to Herceptin®.

21 Jan 20 | BioProcess International reported the launch of biosimilar adalimumab products in the US market in 2023. Drawing from an international profit erosion of 45-48% for Humira® in 2019, AbbVie’s CEO Gonzalez warned stakeholders that biosimilar competition in the US would further impact profits. Gonzalez also noted that the erosion rate in the US would not be directly comparable to European markets as it would be heavily impacted by negotiations with managed care and pharmacy benefit managers.

16 Jan 20 | Health New England, a nonprofit health plan in Massachusetts, announced savings of $1.7 million in the past year by reaching 93% utilisation of biosimilar infliximab.

Jan 20 | Romania’s Competition Council fined Roche $14 million for undermining biosimilar and generic competition related to MabThera® (rituximab) and Herceptin® (trastuzumab).

Get our Pearce IP Blogs & BioBlast® sent directly to your inbox

Subscribe to our Pearce IP Blogs and BioBlast® to receive our updates via email.

Our Latest News